期刊文献+

维持性血液透析患者血清肿瘤标志物水平的研究 被引量:1

下载PDF
导出
摘要 肿瘤标志物主要是由肿瘤组织和细胞产生的异常表达的生物活性物质,这些物质有的不存在于正常人体内而只见于胚胎中,有的在肿瘤患者体内含量超过正常人体内含量。目前临床实验室肿瘤标志物的检测技术主要针对肿瘤相关抗原,这并非肿瘤细胞所特有,而在于肿瘤相关抗原表达的量。但因同一种肿瘤可产生多种肿瘤标志物,不同肿瘤或同一肿瘤的不同组织类型既可产生相同的标志物,也可有不同的标志物。所以至今仍没有一种标志物对肿瘤是完全特异性的。
出处 《中国血液净化》 2007年第11期622-624,共3页 Chinese Journal of Blood Purification
基金 上海市科学自然基金(05ZR14086) 上海市医苑新星基金(02XX46)
  • 相关文献

参考文献16

  • 1Arik N, Adam B, Akpolat T. serum tumor markers in renal failure[J].Int Urol Nephrol, 1996,28(4):601.
  • 2俞小芳,徐夏莲,叶志斌,吴兆龙.肾功能及血液透析对慢性肾脏疾病患者血清肿瘤标志物的影响[J].上海医学,2007,30(2):81-85. 被引量:8
  • 3Lye WC, Tambyah P, Leong SO ,et al. Serum tumor markers in patients on dialysis and kidney transplantation[J]. Adv Perit Dial, 1994,10:109.
  • 4Polenakovic M, Sikole A, Dzikova S, et al. Acquired renal cystic disease and tumor markers in chronic hemodialysis patients[J]. Int J Artif Organs , 1997, 20 (2):96.
  • 5Odagiri E, Jibiki K, Takeda M,et al. Effect of hemodialysis on the concentration of the seven tumor markers carcinoembryonic antigen, alpha-fetoprotein, squamous cell carcinoma-relatedantigen ,neuron-specific enolase, CA125, CA199 and CA153 in uremic patients[J].Am J Nephrol, 1991,11(5):363.
  • 6Nomura J, Koyama A, Ishijima M, et al. Serum levels of five tumor markers for lung cancer in patients with chronic renal failure [J].Oncologyreports, 1998,5(2): 389-392.
  • 7Tzanakis I, Kazoulis S, Girousis N, et al. Prostate specificantigen in hemodialysis patients and the influence of dialysis in its levels[J]. Nephron, 2002,90 (2):230.
  • 8Monath J R, Burkart JM, Freedman BI, et al. Effect s of hemodialysis on prostate-specific antigen [J]. Urology, 1993,42(4):398.
  • 9Djavan B, Shariat S, Ghawidel K, et al. Impact of chronic dialysis on serum PSA , free PSA , and free/total PSA ratio: is prostate cancer detection compromised in patient s receiving long-term dialysis[J]. Urology, 1999, 53 (6):1169.
  • 10Yoshihiro W, Juro N, Wataru T, et al. Mass screening for prostate cancer in patients with end-stage renal disease: a comparative study[J]. BJU Int, 2006, 8(5): 794-797.

二级参考文献21

  • 1张悦,叶志斌,吉俊.肿瘤标记物在原发性肾脏疾病患者中的血清学浓度改变[J].中国临床医学,2005,12(1):135-137. 被引量:10
  • 2Wang EC.Difficulties in analysis of CA125 in diluted samples.Clin Chem,1995,41:1543-1544.
  • 3Visser CE,Brouwer TT,Befjes MG,et al.Cancer antigen 125:a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant,1995,10:64-69.
  • 4Koomen GC,Betjes MG,Zemel D,et al.Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis.Perit Dial Int,1994,14:132-136.
  • 5Nomura F,Koyama A,Ishijima M,et al.Serum levels of five tumor markers for lung cancer in patients with chronic renal failure.Oncol Rep,1998,5:389-392.
  • 6Filella X,Cases A,Molina R,et al.Tumor markers in patients with chronic renal failure.Int J Biol Markers,1990,5:85-88.
  • 7Arik N,Adam B,Akpolat T,et al.Serum tumour markers in renal failure.Int Urol Nephrol,1996,28:601-604.
  • 8Harper L,McIntyre CW,MacDougall IC,et al.Prostate-specific antigen levels in patients receiving long-term dialysis.Br J Urol,1995,76:482-483.
  • 9Sumura M,Yokogi H,Beppu M,et al.Diagnostic value of serum prostate-specific antigen in hemodialysis patients.Int J Urol,2003,10:247-250.
  • 10Bruun L,Bjork T,Lilja H,et al.Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.Nephrol Dial Transplant,2003,18:598-603.

共引文献13

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部